Literature DB >> 28298057

Defining the "Substantial Clinical Benefit" After Arthroscopic Treatment of Femoroacetabular Impingement.

Benedict U Nwachukwu1, Brenda Chang1, Kara Fields1, Brian J Rebolledo1, Danyal H Nawabi1, Bryan T Kelly1, Anil S Ranawat1.   

Abstract

BACKGROUND: The minimal clinically important difference (MCID) has been defined in orthopaedics and is the smallest change that a patient considers meaningful. Less is known about improvements that the patient perceives as clinically considerable, or the substantial clinical benefit (SCB). For the young, highly functioning patient cohort with femoroacetabular impingement (FAI), the SCB is an important measure of clinical success.
PURPOSE: To derive the SCB for FAI treatment and identify outcome score thresholds and patient variables predictive of the SCB. STUDY
DESIGN: Cohort study (diagnosis); Level of evidence, 2.
METHODS: The modified Harris Hip Score (mHHS), the Hip Outcome Score activities of daily living (HOS-ADL) and sport (HOS-Sport) subscales, and the international Hip Outcome Tool (iHOT-33) were prospectively administered to 364 patients with a minimum 1-year follow-up. At 1 year postoperatively, patients graded their hip function based on several anchor responses such as "no change" and "much improved." The SCB was defined as the change on each outcome tool that equated to the difference between "no change" and "much improved" on the health transition question. Receiver operating characteristic analysis with area under the curve (AUC) was used to identify optimal values that were most representative of the SCB. Multivariable analysis identified patient variables predictive of the SCB.
RESULTS: The net change in outcome scores corresponding to the SCB for the mHHS, HOS-ADL, HOS-Sport, and iHOT-33 was 19.8, 10.0, 29.9, and 24.5, respectively. The following postoperative outcome scores demonstrated excellent distinction (AUC >0.8) between "no change" and "much improved" and thus were considered absolute values for the postoperative SCB: 82.5 (mHHS), 93.3 (HOS-ADL), 84.4 (HOS-Sport), and 63.5 (iHOT-33). Preoperative scores on the HOS-ADL (83.3) and HOS-Sport (50.0) were significant threshold cutoffs, above which attaining the SCB became less likely. Younger age and lower Outerbridge grade were predictive of achieving the SCB.
CONCLUSION: The SCB has not been previously defined in the hip preservation literature and is complementary to the MCID as the upper bound for clinically significant improvement. We identified predictive preoperative and diagnostic postoperative outcome scores for the SCB that can be used to manage patient expectations and grade outcomes. These findings are objective criteria for defining clinical success after arthroscopic FAI treatment.

Entities:  

Keywords:  epidemiology; femoroacetabular impingement; hip arthroscopic surgery; outcome; quality of life; substantial clinical benefit

Mesh:

Year:  2017        PMID: 28298057     DOI: 10.1177/0363546516687541

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  34 in total

1.  Value-based Health Care: Moving Beyond "Minimum Clinically Important Difference" to a Tiered System of Evaluating Successful Clinical Outcomes.

Authors:  David N Bernstein; Benedict U Nwachukwu; Kevin J Bozic
Journal:  Clin Orthop Relat Res       Date:  2019-05       Impact factor: 4.176

2.  Computerized Adaptive Testing for Patient Reported Outcomes in Ankle Fracture Surgery.

Authors:  Elizabeth B Gausden; Ashley Levack; Benedict U Nwachukwu; Danielle Sin; David S Wellman; Dean G Lorich
Journal:  Foot Ankle Int       Date:  2018-07-04       Impact factor: 2.827

3.  What Are the Minimal and Substantial Improvements in the HOOS and KOOS and JR Versions After Total Joint Replacement?

Authors:  Stephen Lyman; Yuo-Yu Lee; Alexander S McLawhorn; Wasif Islam; Catherine H MacLean
Journal:  Clin Orthop Relat Res       Date:  2018-12       Impact factor: 4.176

4.  Health-Related Quality of Life After Hip Arthroscopy for Femoroacetabular Impingement: A Systematic Review and Meta-analysis.

Authors:  Chetan Gohal; Saif Shamshoon; Muzammil Memon; Jeffrey Kay; Nicole Simunovic; Filippo Randelli; Olufemi R Ayeni
Journal:  Sports Health       Date:  2019-05-02       Impact factor: 3.843

5.  How Should We Define Clinically Significant Outcome Improvement on the iHOT-12?

Authors:  Benedict U Nwachukwu; Brenda Chang; Edward C Beck; William H Neal; Kamran Movassaghi; Anil S Ranawat; Shane J Nho
Journal:  HSS J       Date:  2018-11-15

6.  Acetabular labral reconstruction using the indirect head of the rectus femoris tendon significantly improves patient reported outcomes.

Authors:  Eyal Amar; Thomas G Sampson; Zachary T Sharfman; Alyssa Caplan; Noa Rippel; Ran Atzmon; Michael Drexler; Ehud Rath
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-07-17       Impact factor: 4.342

7.  Editorial Commentary: Delivering the PROMIS for Patients With Shoulder Disorders-Fool's Gold, a Mirage, or an Oasis.

Authors:  David Kovacevic
Journal:  Arthroscopy       Date:  2021-04       Impact factor: 4.772

Review 8.  Reporting Clinical Significance in Hip Arthroscopy: Where Are We Now?

Authors:  Breanna A Polascik; Jeffrey Peck; Nicholas Cepeda; Stephen Lyman; Daphne Ling
Journal:  HSS J       Date:  2020-04-12

9.  The Minimal Clinically Important Difference, Substantial Clinical Benefit, and Patient-Acceptable Symptomatic State after Medial Patellofemoral Ligament Reconstruction.

Authors:  Justin M Walsh; Hailey P Huddleston; Mohamad M Alzein; Stephanie E Wong; Brian Forsythe; Nikhil N Verma; Brian J Cole; Adam B Yanke
Journal:  Arthrosc Sports Med Rehabil       Date:  2022-02-05

10.  Preoperative Hip Extension Strength Is an Independent Predictor of Achieving Clinically Significant Outcomes After Hip Arthroscopy for Femoroacetabular Impingement Syndrome.

Authors:  Edward C Beck; Benedict U Nwachukwu; Laura M Krivicich; Philip Malloy; Sunikom Suppauksorn; Kyleen Jan; Shane J Nho
Journal:  Sports Health       Date:  2020-05-11       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.